3 ETFs That Are Being Killed By Their Expense Ratios
Mutual funds and ETFs have been a great way to provide loads of investing options to investors everywhere but if they have a drawback it can be how expenses and fees can eat into shareholder […]
Mutual funds and ETFs have been a great way to provide loads of investing options to investors everywhere but if they have a drawback it can be how expenses and fees can eat into shareholder […]
The concept of a “fund of funds” investment product has been around for some time. The most obvious example of this product is the target retirement date fund that almost every major investment management firm […]
Target date funds have built a reputation as one of the easiest choices that both novice and experienced investors could make when selecting a vehicle for retirement. They provide an investment that you can almost […]
When it comes to retirement planning, I’m a firm believer that simpler is better. Many advisors will recommend a platter of different fund and ETF choices that cover nearly all asset classes and risk levels. […]
Companies, it seems, have had an insatiable appetite for buying back their own shares lately. It’s a strategy that is a bit of a double-edged sword. It’s great for shareholders as a reduced share count […]
Market volatility as measured by the CBOE’s Volatility Index (VIX) has been on the rise thus far in 2015. Over the past couple of years, volatility has remained relatively tame as the market was marching […]
With biotechnology continuing to be the hot sector heading into 2015, we’ve seen several investment firms looking to capitalize on the trend. I’ve profiled a pair of those new biotech ETFs launched just recently here […]
ETF providers seem eager to take advantage of the popularity of biotechs recently. The biotech sector as measured by the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) was up 34% in 2014 and has seen its assets […]
Biotechnology stocks have soared this past year – the iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) returned an impressive 34% in 2014 – so it’s not surprising that companies are stepping up their biotech offerings in […]
Investors should be well aware of the dangers that come with chasing yields. In a vacuum, a dividend yield may look fantastic but a look under the sheets can reveal a great deal of ugliness. […]
Copyright © 2024 | MH Magazine WordPress Theme by MH Themes